Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume – Here’s What Happened

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) saw unusually-high trading volume on Monday . Approximately 198,627 shares changed hands during mid-day trading, an increase of 126% from the previous session’s volume of 87,898 shares.The stock last traded at $7.8350 and had previously closed at $8.03.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Citigroup initiated coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective on the stock. UBS Group dropped their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. Finally, Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Performance

The company has a 50 day simple moving average of $9.56 and a two-hundred day simple moving average of $11.52.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in Telix Pharmaceuticals in the third quarter worth $1,883,000. Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter worth $3,037,000. Portland Investment Counsel Inc. acquired a new stake in Telix Pharmaceuticals in the 3rd quarter worth $1,225,000. Lazard Asset Management LLC bought a new position in Telix Pharmaceuticals during the third quarter valued at about $1,097,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $975,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.